2020年去纤苷售价多少？

It was first developed by Italy's Gentium Pharmaceuticals and was approved for marketing in the European Union in October 2013. It was approved for marketing in the United States by the U.S. Food and Drug Administration (FDA) on March 30, 2016.

Defibrotide is the first drug approved by the U.S. FDA to treat severe hepatic veno-occlusive disease. It is used for adult or pediatric patients with hepatic vein occlusion (VOD) after blood or bone marrow hematopoietic stem cell transplantation (HSCT) and accompanied by renal or pulmonary function abnormalities. At the same time, the drug has also received "orphan drug" qualifications. How much will defibrotide cost in 2020?

Price of defibrotide: According to Medical Companion Travel, defibrotide has been marketed abroad. The price of defibrotide listed abroad is about 22,000. Due to the floating exchange rate, the price is different. Please consult Medical Companion Travel for the specific price! 

How to administer defibrotide:

1. The recommended dose of defibrotide for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol.

Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrotide until resolution of VOD or up to a maximum of 60 days.

2. Medication instructions

Defibrotide must be diluted prior to infusion;

Prior to administration of defibrotide, confirm that the patient is not experiencing clinically significant bleeding and is hemodynamically stable on no more than one vasopressor.

Defibrotide was administered by constant intravenous infusion over a 2-hour period.

Do not coadminister with other intravenous medications at the same time and in the same intravenous line.   

Recommended related hot articles: /newsDetail/74966.html